A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab Maintenance Following First-Line Platinum Based Chemotherapy in Patients With Metastatic Squamous - Non-Small Cell Lung Cancer (sNSCLC)
Phase of Trial: Phase II
Latest Information Update: 16 Jan 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms PRIMUS
- 10 Jun 2017 Biomarkers information updated
- 28 Jul 2016 Status changed from not yet recruiting to recruiting.
- 04 Jan 2016 Planned initiation date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.